Drug Profile
Research programme: cancer radiopharmaceuticals - Progenics Pharmaceuticals
Alternative Names: 131-I-MIP-1375; 99mTc-MIP-1340; 99mTc-MIP-1407; MIP-1340; MIP-1375; MIP-1407; MIP-1555; MIP-1558; MIP-220; Radiolabelled SSTR2 agonist and antagonist peptides - Progenics; Tc-99m-PSMA inhibitors - ProgenicsLatest Information Update: 19 Jun 2020
Price :
$50
*
At a glance
- Originator Molecular Insight Pharmaceuticals
- Developer Progenics Pharmaceuticals
- Class Diagnostic agents; Imaging agents; Peptides; Radiopharmaceutical diagnostics
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuroendocrine tumours; Prostate cancer
Most Recent Events
- 16 Jun 2020 Progenics Pharmaceuticals has been acquired by Lantheus Holdings
- 28 Jul 2018 No recent reports of development identified for preclinical development in Neuroendocrine-tumours(Diagnosis) in USA (Parenteral)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Prostate-cancer in USA (Parenteral)